Mining biotech's data mother lode

A EU-sponsored project has developed a suite of tools that will enable biotech companies to mine through vast quantities of data created by modern life-science labs to find the nuggets of genetic gold that lie within.

The BioGrid project brought together six partners from the UK, Germany, Cyprus and The Netherlands to address one of the key problems facing the life sciences today.

"How to integrate the huge volume of disparate data – on gene expression, protein interactions and the vast output of literature both inside and outside laboratories – to find out what is important," says Dr Michael Schroeder, Professor of the Bioinformatics group at Dresden Technical University and coordinator of this IST-funded project.

"I attended a workshop recently, held by the W3 consortium, and many of the companies there said that this was the biggest problem they face."

Currently, pharmaceutical and biotech companies produce vast quantities of raw data on the problems that interests them. Microarrays process thousands of samples to discover what genes are over expressing.

These over-expressing genes – numbering sometimes in their thousands, too – create proteins. The researchers then need to discover what protein interactions are taking place among all the different proteins created by the over-expressing genes. This is not trivial.

If a researcher can identify protein interactions they then need to do a search on their company intranet to see what other work company labs have produced relevant to the topic. Since the data output at biotech labs is vast, this is also not trivial.

Finally, the researcher must perform a search of academic journals to find relevant journal papers. Currently PubMed, the most important public literature database available, has 15,000,000 entries, and the number is growing every day. Finding relevant data there is again not a trivial task.

Dr Schroeder gives an example. "The medical faculty here were studying pancreatic tumours. They found 1,000 genes over expressing. Using our software they were able to find, among others, three protein interactions that were particularly relevant. Using our literature search ontology they were able to discover that two of these interactions were novel. They are now going to study these novel interactions more closely," he says.

BioGrid explained
This is how the project will help companies integrate all the data they need to make relevant discoveries using a BioGrid. A BioGrid is essentially a data and computational Grid created through a suite of tools developed by the project.

Biotech and life science companies will use these tools internally to integrate data. They can then also use the same tools to create ad-hoc distributed processing networks to crank through computationally-intense problems, if needed.

Here's how it works. One element of the software suite analyses over-expressing genes discovered during micro assays to establish what proteins become encoded. This uses standard techniques.

A second analysis tool in the suite predicts what possible protein-protein interactions are taking place. This is novel. When a gene encodes a protein, the protein folds up into a unique shape, forming a 3D structure. This structure can only interact, or fit, with some proteins, but not others, like pieces of a jigsaw puzzle.

BioGrid's protein interaction software includes a database of the 20,000 known protein structures and uses that database to identify which ones could potentially interact, among the thousands of proteins created by the over-expressing genes. This focuses research efforts on the most interesting candidates for a particular problem, like, for example, pancreatic tumours.

A smart way to search
Once interesting potential protein interactions are known, BioGrid's ontology-based search technology can mine company or journal data for any relevant information. The Gene Ontology (GO) was established by the life sciences as a vocabulary to describe all the different genetic processes. There are 20,000 terms in this vocabulary so far.

"The problem is researchers never use exact terms from the Gene Ontology to do their search of the literature. Our innovation was to create an algorithm that intelligently matches the terms used by researchers to the Gene Ontology," says Dr Schroeder.

This smart search produces a list of all the possible GO terms and lists all the articles relevant to that specific term. Researchers are presented with a vast quantity of information broken down by sub-topic, so they can quickly drill down to the most relevant information.

Linking all these software tools together is a rules-based Java scripting language called Prova, also developed by the BioGrid team. It is the glue the sticks the Gene Expression, Protein Interaction and ontology-based literature analysis together into an integrated, cohesive unit. "It's an open source language, available at www.prova.ws, and about 20 groups are using it around the world right now. We made it open source because you need to develop a community to keep a programming language alive," says Dr Schroeder.

So biotech companies can establish their own BioGrids on their intranet, some of the researchers involved in BioGrid created the spin-off company Molgenis supported by a BioPartner first stage Grant. In addition other partners are in the process of obtaining seed funding for a spin-off company called Transinsight.

"BioGrid is a knowledge Grid that offers the proper software and support so that companies can do rapid prototyping for their data-integration and large computations," says Dr Schroeder. "Transinsight will continue working on new, innovative and novel solutions to data problems faced by the life sciences industry," hopes Dr Schroeder. "The company will look at natural language processing and the semantic Grid for the life sciences. It is currently running two feasibility studies with two international customers. Molgenis provides software to support the storage and analysis of gene expression data."

Many of the tools developed by BioGrid are available for public use. The ontology-based search is available at GoPubMed.org, while the protein interaction database is at Scoppi.org. But GoPubMed is limited to 100 searches while Scoppi does not include the predictive analysis tool. These limitations will not be there for commercial clients. For those, BioGrid offers an earthmover for data mining.

Contact:
Michael Schroeder
Professor in Bioinformatics
Biotec/Dept. of Computing, TU Dresden
Tatzberg 47-51
D-01307 Dresden
Germany
Tel: +49-351-46340060
Fax: +49-351-46340061
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: IST Results Portal

Most Popular Now

Welcome Evo, Generative AI for the Genom…

Brian Hie runs the Laboratory of Evolutionary Design at Stanford, where he works at the crossroads of artificial intelligence and biology. Not long ago, Hie pondered a provocative question: If...

We could Soon Use AI to Detect Brain Tum…

A new paper in Biology Methods and Protocols, published by Oxford University Press, shows that scientists can train artificial intelligence (AI) models to distinguish brain tumors from healthy tissue. AI...

Telehealth Significantly Boosts Treatmen…

New research reveals a dramatic improvement in diagnosing and curing people living with hepatitis C in rural communities using both telemedicine and support from peers with lived experience in drug...

Research Study Shows the Cost-Effectiven…

Earlier research showed that primary care clinicians using AI-ECG tools identified more unknown cases of a weak heart pump, also called low ejection fraction, than without AI. New study findings...

AI can Predict Study Results Better than…

Large language models, a type of AI that analyses text, can predict the results of proposed neuroscience studies more accurately than human experts, finds a new study led by UCL...

New Guidance for Ensuring AI Safety in C…

As artificial intelligence (AI) becomes more prevalent in health care, organizations and clinicians must take steps to ensure its safe implementation and use in real-world clinical settings, according to an...

Remote Telemedicine Tool Found Highly Ac…

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a...

Philips Aims to Advance Cardiac MRI Tech…

Royal Philips (NYSE: PHG, AEX: PHIA) and Mayo Clinic announced a research collaboration aimed at advancing MRI for cardiac applications. Through this investigation, Philips and Mayo Clinic will look to...

New Study Reveals Why Organisations are …

The slow adoption of blockchain technology is partly driven by overhyped promises that often obscure the complex technological, organisational, and environmental challenges, according to research from the University of Surrey...

Deep Learning Model Accurately Diagnoses…

Using just one inhalation lung CT scan, a deep learning model can accurately diagnose and stage chronic obstructive pulmonary disease (COPD), according to a study published today in Radiology: Cardiothoracic...

Shape-Changing Device Helps Visually Imp…

Researchers from Imperial College London, working with the company MakeSense Technology and the charity Bravo Victor, have developed a shape-changing device called Shape that helps people with visual impairment navigate...

Bayer Acquires HiDoc Technologies and Ca…

Bayer is today announcing that it plans to acquire HiDoc Technologies GmbH in the first quarter of 2025 and to start commercialization of the digital health application, Cara Care®. Cara...